Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[The proportion of individuals with innate slow mEPHX activity (homozygotes) was significantly higher in both the COPD group and the emphysema group than in the control group (COPD 13 [19%] vs control 13 [6%]; emphysema 21 [22%] vs 13 [6%]).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP727094.RAvqXB7akb5EtAktRqXehLAdTsG7Z_IoaP6BZHJd00Rnc130_assertion description "[The proportion of individuals with innate slow mEPHX activity (homozygotes) was significantly higher in both the COPD group and the emphysema group than in the control group (COPD 13 [19%] vs control 13 [6%]; emphysema 21 [22%] vs 13 [6%]).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP727094.RAvqXB7akb5EtAktRqXehLAdTsG7Z_IoaP6BZHJd00Rnc130_provenance.
• NP867246.RAvBt391YTjsG3BeroCKwQFDW4V4LDMqBkeGJ7sonhNuk130_assertion description "[The proportion of individuals with innate slow mEPHX activity (homozygotes) was significantly higher in both the COPD group and the emphysema group than in the control group (COPD 13 [19%] vs control 13 [6%]; emphysema 21 [22%] vs 13 [6%]).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP867246.RAvBt391YTjsG3BeroCKwQFDW4V4LDMqBkeGJ7sonhNuk130_provenance.
• NP440106.RAmnmyQN7FkwTO8XMfZP6o8rZSbn0lv-FXJLcSrvCixlA130_assertion description "[The proportion of individuals with innate slow mEPHX activity (homozygotes) was significantly higher in both the COPD group and the emphysema group than in the control group (COPD 13 [19%] vs control 13 [6%]; emphysema 21 [22%] vs 13 [6%]).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP440106.RAmnmyQN7FkwTO8XMfZP6o8rZSbn0lv-FXJLcSrvCixlA130_provenance.
• assertion description "[The proportion of individuals with innate slow mEPHX activity (homozygotes) was significantly higher in both the COPD group and the emphysema group than in the control group (COPD 13 [19%] vs control 13 [6%]; emphysema 21 [22%] vs 13 [6%]).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[The proportion of individuals with innate slow mEPHX activity (homozygotes) was significantly higher in both the COPD group and the emphysema group than in the control group (COPD 13 [19%] vs control 13 [6%]; emphysema 21 [22%] vs 13 [6%]).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[The proportion of individuals with innate slow mEPHX activity (homozygotes) was significantly higher in both the COPD group and the emphysema group than in the control group (COPD 13 [19%] vs control 13 [6%]; emphysema 21 [22%] vs 13 [6%]).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[The proportion of individuals with innate slow mEPHX activity (homozygotes) was significantly higher in both the COPD group and the emphysema group than in the control group (COPD 13 [19%] vs control 13 [6%]; emphysema 21 [22%] vs 13 [6%]).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP418007.RAZ6_n1AeMIUlzciBTB61WQ-NOuR2nKMjgRF0eZsvVt-Q130_assertion description "[The proportion of individuals with innate slow mEPHX activity (homozygotes) was significantly higher in both the COPD group and the emphysema group than in the control group (COPD 13 [19%] vs control 13 [6%]; emphysema 21 [22%] vs 13 [6%]).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP418007.RAZ6_n1AeMIUlzciBTB61WQ-NOuR2nKMjgRF0eZsvVt-Q130_provenance.
• NP445532.RAJ_QUrOFiPu2PIZyGNhhIQV1MUlr6tNOIYzLbFA_eMyI130_assertion description "[The proportion of individuals with innate slow mEPHX activity (homozygotes) was significantly higher in both the COPD group and the emphysema group than in the control group (COPD 13 [19%] vs control 13 [6%]; emphysema 21 [22%] vs 13 [6%]).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP445532.RAJ_QUrOFiPu2PIZyGNhhIQV1MUlr6tNOIYzLbFA_eMyI130_provenance.
• NP13710.RAab8KLSeaAO7Ht5mB1i8WRb6z1MeKm-lZN3L8yrqA_Bk130_assertion description "[The proportion of individuals with innate slow mEPHX activity (homozygotes) was significantly higher in both the COPD group and the emphysema group than in the control group (COPD 13 [19%] vs control 13 [6%]; emphysema 21 [22%] vs 13 [6%]).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP13710.RAab8KLSeaAO7Ht5mB1i8WRb6z1MeKm-lZN3L8yrqA_Bk130_provenance.
• NP377412.RAUzpyQwuDOyk3jLmARF80DD9n8u7Cq6xOZa44z1L3Y7k130_assertion description "[The proportion of individuals with innate slow mEPHX activity (homozygotes) was significantly higher in both the COPD group and the emphysema group than in the control group (COPD 13 [19%] vs control 13 [6%]; emphysema 21 [22%] vs 13 [6%]).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP377412.RAUzpyQwuDOyk3jLmARF80DD9n8u7Cq6xOZa44z1L3Y7k130_provenance.
• NP1003324.RAWLhrhOnC-iu-O6OcHLGFkEt7ARPywQMzZw2ySX0jmP4130_assertion description "[The proportion of individuals with innate slow mEPHX activity (homozygotes) was significantly higher in both the COPD group and the emphysema group than in the control group (COPD 13 [19%] vs control 13 [6%]; emphysema 21 [22%] vs 13 [6%]).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1003324.RAWLhrhOnC-iu-O6OcHLGFkEt7ARPywQMzZw2ySX0jmP4130_provenance.
• NP249441.RAUDh0yePUXMXIPBIhPS-9yLW6FzcAmF8iYhOsakJqVyo130_assertion description "[The proportion of individuals with innate slow mEPHX activity (homozygotes) was significantly higher in both the COPD group and the emphysema group than in the control group (COPD 13 [19%] vs control 13 [6%]; emphysema 21 [22%] vs 13 [6%]).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP249441.RAUDh0yePUXMXIPBIhPS-9yLW6FzcAmF8iYhOsakJqVyo130_provenance.
• NP249442.RAYUtnivExIiMOEpSgGKnI2sFtu1P-m1mhK5C-69HVA5E130_assertion description "[The proportion of individuals with innate slow mEPHX activity (homozygotes) was significantly higher in both the COPD group and the emphysema group than in the control group (COPD 13 [19%] vs control 13 [6%]; emphysema 21 [22%] vs 13 [6%]).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP249442.RAYUtnivExIiMOEpSgGKnI2sFtu1P-m1mhK5C-69HVA5E130_provenance.
• assertion description "[The proportion of individuals with innate slow mEPHX activity (homozygotes) was significantly higher in both the COPD group and the emphysema group than in the control group (COPD 13 [19%] vs control 13 [6%]; emphysema 21 [22%] vs 13 [6%]).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[The proportion of individuals with innate slow mEPHX activity (homozygotes) was significantly higher in both the COPD group and the emphysema group than in the control group (COPD 13 [19%] vs control 13 [6%]; emphysema 21 [22%] vs 13 [6%]).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[The proportion of individuals with innate slow mEPHX activity (homozygotes) was significantly higher in both the COPD group and the emphysema group than in the control group (COPD 13 [19%] vs control 13 [6%]; emphysema 21 [22%] vs 13 [6%]).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[The proportion of individuals with innate slow mEPHX activity (homozygotes) was significantly higher in both the COPD group and the emphysema group than in the control group (COPD 13 [19%] vs control 13 [6%]; emphysema 21 [22%] vs 13 [6%]).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP249443.RAoYUL9SoXiAdJ0EoggVtqViXZYWgDLuP1kwk_QBCGU7I130_assertion description "[The proportion of individuals with innate slow mEPHX activity (homozygotes) was significantly higher in both the COPD group and the emphysema group than in the control group (COPD 13 [19%] vs control 13 [6%]; emphysema 21 [22%] vs 13 [6%]).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP249443.RAoYUL9SoXiAdJ0EoggVtqViXZYWgDLuP1kwk_QBCGU7I130_provenance.
• NP1003321.RAGnVs7mfjmHhihSha3Pv02P6TfIAQndnYPJPQvyEe7OQ130_assertion description "[The proportion of individuals with innate slow mEPHX activity (homozygotes) was significantly higher in both the COPD group and the emphysema group than in the control group (COPD 13 [19%] vs control 13 [6%]; emphysema 21 [22%] vs 13 [6%]).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1003321.RAGnVs7mfjmHhihSha3Pv02P6TfIAQndnYPJPQvyEe7OQ130_provenance.
• NP1003322.RAIInwOYt0b0FTRcxlHjnTFhw8bjo4xuoXoXQXnunqbrk130_assertion description "[The proportion of individuals with innate slow mEPHX activity (homozygotes) was significantly higher in both the COPD group and the emphysema group than in the control group (COPD 13 [19%] vs control 13 [6%]; emphysema 21 [22%] vs 13 [6%]).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1003322.RAIInwOYt0b0FTRcxlHjnTFhw8bjo4xuoXoXQXnunqbrk130_provenance.
• NP1003323.RA8Iy1jQ5bewAd-aGaNqhVnQCqePdDAr0LrZ_qDhp2J5I130_assertion description "[The proportion of individuals with innate slow mEPHX activity (homozygotes) was significantly higher in both the COPD group and the emphysema group than in the control group (COPD 13 [19%] vs control 13 [6%]; emphysema 21 [22%] vs 13 [6%]).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1003323.RA8Iy1jQ5bewAd-aGaNqhVnQCqePdDAr0LrZ_qDhp2J5I130_provenance.
• NP1380004.RAPskf3WKBbXjb2RButhFvlQ14mSSnr3-H_qacQsxB1fM130_assertion description "[The proportion of individuals with innate slow mEPHX activity (homozygotes) was significantly higher in both the COPD group and the emphysema group than in the control group (COPD 13 [19%] vs control 13 [6%]; emphysema 21 [22%] vs 13 [6%]).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1380004.RAPskf3WKBbXjb2RButhFvlQ14mSSnr3-H_qacQsxB1fM130_provenance.
• NP1380007.RAGtzF3aF1hOntd9waKA1iCtobkPpjHPTcdr1yI9ShUUQ130_assertion description "[The proportion of individuals with innate slow mEPHX activity (homozygotes) was significantly higher in both the COPD group and the emphysema group than in the control group (COPD 13 [19%] vs control 13 [6%]; emphysema 21 [22%] vs 13 [6%]).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1380007.RAGtzF3aF1hOntd9waKA1iCtobkPpjHPTcdr1yI9ShUUQ130_provenance.
• NP249440.RA-U24gdU-zh76b227TIrOG3kW1XsvR3khtxCKsvLkrWA130_assertion description "[The proportion of individuals with innate slow mEPHX activity (homozygotes) was significantly higher in both the COPD group and the emphysema group than in the control group (COPD 13 [19%] vs control 13 [6%]; emphysema 21 [22%] vs 13 [6%]).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP249440.RA-U24gdU-zh76b227TIrOG3kW1XsvR3khtxCKsvLkrWA130_provenance.
• NP1380005.RAzUX949rY1xT4zei8uw4XFxYUgJPg3d-Vi9eNa_aJZkA130_assertion description "[The proportion of individuals with innate slow mEPHX activity (homozygotes) was significantly higher in both the COPD group and the emphysema group than in the control group (COPD 13 [19%] vs control 13 [6%]; emphysema 21 [22%] vs 13 [6%]).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1380005.RAzUX949rY1xT4zei8uw4XFxYUgJPg3d-Vi9eNa_aJZkA130_provenance.